Shedding Light on Why Immunotherapy Sometimes Fails

Immune checkpoint inhibitors have revolutionized cancer treatment, but not all patients respond equally. Now, researchers from Japan have explored why two anti-PD-L1 antibodies, which target the same immune pathway, produce vastly different therapeutic outcomes in a mouse cancer model. They found that an immune mechanism known as antibody-dependent cellular cytotoxicity can inadvertently destroy antitumor immune cells. These findings underscore the importance of selecting antibody drugs that minimize off-target effects to improve the efficacy of immunotherapy.